40th Annual Miami Breast Cancer Conference® - Abstracts

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

ByPhilippe Aftimos,Javier Cortes,Francois Clement Bidard,Virginia Kaklamani, MD, DSc,Aditya Bardia, MD, MPH,Alberto J. Montero, MD, MBA, CPHQ,Joo Hyuk Sohn,Giulia Tonini,Krzysztof J. Grzegorzewski,Patrick Neven, MD, PhD

April 28th 2023

2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data

ByTalal Ahmed,Daniel Stover,Adam Hockenberry,Matthew Mackay,Raphael Pelossof,Halla Nimeiri,James L. Chen,Rotem Ben-Shachar,Massimo Cristofanilli, MD

April 28th 2023

3 Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience

BySabah Alaklabi,Joseph Elijah,Arya Mariam Roy,Adrienne Groman,Shipra Gandhi

April 28th 2023

4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study

ByJamil Asselah,Cynthia X. Ma, MD, PhD,Zbigniew Nowecki,Robert Huisden,Ross Stewart,Petra Vuković,Peter Schmid, MD

April 28th 2023

5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study

ByAlexandra Guarin,Katie Mycock,Gary Milligan,Gavin Taylor-Stokes,Christian Atkinson

April 28th 2023

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

ByAditya Bardia, MD, MPH,Francois Clement Bidard,Patrick Neven, MD, PhD,Alberto J. Montero, MD, MBA, CPHQ,Joo Hyuk Sohn,Philippe Aftimos,Javier Cortes,Simona Scartoni,Nassir Habboubi,Virginia Kaklamani, MD, DSc

April 28th 2023

8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

ByAditya Bardia, MD, MPH,Ian E. Krop,Funda Meric-Bernstam, MD,Anthony W. Tolcher,Toru Mukohara,Aaron Lisberg,Toshio Shimizu,Erika P. Hamilton, MD,Alexander Spira, MD, PhD, FACP,Takahiro Kogawa

April 28th 2023

9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

ByAditya Bardia, MD, MPH,Ian E. Krop,Dejan Juric,Takahiro Kogawa,Erika P. Hamilton, MD,Alexander Spira, MD, PhD, FACP,Toru Mukohara,Takuya Tsunoda,Senthil Damodaran,Funda Meric-Bernstam, MD

April 28th 2023

11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above

ByAdam M. Brufsky, MD, PhD,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Rachel M. Layman,Hope S. Rugo, MD

April 28th 2023

12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)

ByLisa A. Carey, MD,Tomas Pascual,Daniel Stover,Astrid Thuerigen,Charles Perou,Eva Ciruelos,Ana Casas,Patty Spears,Estelle Roux,Faye Su,Hullin Hu,Yen-Shen Lu,Sara M. Tolaney, MD, MPH,Ann H. Partridge, MD, MPH,Guillermo Villacampa,Juan Manuel Ferrero-Cafiero,Aleix Prat

April 28th 2023

13 Improved Sensitivity in Identification of ER- and HER2- Expressing Metastatic Breast Cancers With a Combination of Cell & Cell-Free Liquid Biopsy Analysis

ByGiuseppe Di Caro,Ernest Lam,Kandra Horne,Stefan Gluck,Megan Slade,Rick Wenstrup,Lee Schwartzberg, MD, FACP

April 28th 2023

16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy

ByMelissa Gao,Yen-Shen Lu,Eznal Izwadi Bin Mohd Mahidin,Hamdy Abdel Azim,Yesim Eralp,Yoon Sim Yap,Seock-Ah Im,Julie Rihani,James Bowles,Teresa Delgar Alfaro,Jiwen Wu,Khemaies Slimane,Nagi El Saghir

April 28th 2023

17 A Clinical Systematic Literature Review of Treatments Among Patients With Advanced/ Metastatic HER2+ Breast Cancer

ByKerigo Ndirangu,Rachel Goldgrub,Vanita Tongbram,Rajee Antony,Bagrat Lalayan,Joyce A. O’Shaughnessy,Sarah E. Schellhorn

April 28th 2023

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

ByErika P. Hamilton, MD,Lajos Pusztai, MD, DPhil,Hatem Soliman, MD,Sara A. Hurvitz, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Priya Marreddy,Tarek Sahmoud, MD,Nuhad Ibrahim, MD

April 28th 2023

21 TIP ELECTRA: An Open- Label, Multicenter, Phase 1b/2 Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2– Negative (HER2–) Breast Cancer

ByErika P. Hamilton, MD,Sung-Bae Kim,Neelima Vidula, MD,Simona Scartoni,Tarek Sahmoud, MD,Bartomeu Piza Vallespir,Kathy Puyana Theall,Nassir Habboubi,Nuhad Ibrahim, MD

April 27th 2023

24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study

BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han

April 27th 2023

25 Real-world BRCA1/2 Testing Patterns in HER2–Negative Early- Stage Breast Cancer (eBC) Patients

ByGieira S. Jones,Liam C. Lee,Erin Alwon,Brandon Wang,Poras Dave,Sandy English,Prateesh Varughese,Simon Blanc,Arthur Sillah

April 27th 2023

26 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), Vs Investigator’s Choice of Endocrine Monotherapy for ER+/HER2– Advanced/ Metastatic Breast Cancer (mBC)

ByVirginia Kaklamani, MD, DSc,Aditya Bardia, MD, MPH,Phillippe Aftimos,Javier Cortes,Patrick Neven, MD, PhD,Alberto J. Montero, MD, MBA, CPHQ,Joo Hyuk Sohn,Giulia Tonini,Krzysztof J. Grzegorzewski,François-Clément Bidard

April 27th 2023

27 TIP XMT-1660: A Phase 1b Trial of a B7-H4 Targeted Antibody- Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers

ByKevin Kalinsky, MD, MS,Alexander Spira, MD, PhD, FACP,Sylvia Adams,Nour Abuhadra,Antonio Giordano,Ritesh Parajuli,Heather Han,Amy Weise,Kate Josephs,Erika P. Hamilton, MD

April 27th 2023

28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

ByKevin Kalinsky, MD, MS,Erika P. Hamilton, MD,Laura Spring,Peter A. Fasching,Sandra Franco, MD,Richard De Boer,Javier Cortes,Dejan Juric,Aditya Bardia, MD, MPH,Sina Haftchenary,Agnes Lteif,Juan Pablo Zarate,Liyi Cen,Patrick Neven, MD, PhD

April 27th 2023

31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

ByAditya Bardia, MD, MPH,Lajos Pusztai, MD, DPhil,Kathy S. Albain, MD,Kevin Kalinsky, MD, MS,Dawn Herman,William Barlow,Claudine Isaacs, MD,Micah Maxwell,Nadia Harbeck, MD, PhD,Priyanka Sharma, MD

April 27th 2023

33 Real-world Patient Characteristics, Treatment Patterns, and Outcomes Among Patients With Metastatic Breast Cancer and BRCA Mutations Treated Off-label With Talazoparib

ByReshma L. Mahtani, DO ,Jasmina Ivanova,Angelica Falkenstein,Alexander Niyazov,Joanne C. Ryan,Jonathan Kish,Ajeet Gajra,Parisa Asgarisabet,Kristin M. Zimmerman Savill

April 27th 2023

35 TIP A Pragmatic Clinical Trial to Determine the Best Treatment Decision in Relapsed Metastatic Breast Cancer With Discordant Tumor Receptors

ByT. Allen Pannell, Jr.

April 27th 2023

37 Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined With Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies

ByDavid J. Portman,Senthil Damodaran,Paul V. Plourde,Halle C. F. Moore, MD,Ian C. Anderson

April 27th 2023

48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study

BySara M. Tolaney, MD, MPH,Peter Schmid, MD,Javier Cortes,Frederik Marmé,Hope S. Rugo, MD,Mafalda Oliveira,Delphine Loirat,Komal Jhaveri,Oh Kyu Yoon,Monica Motwani,Hao Wang,Rosemary Delaney,Aditya Bardia, MD, MPH

April 27th 2023

50 Pooled Exploratory Analysis of Survival in Patients (pts) With HR+/ HER2− Advanced Breast Cancer (ABC) and Visceral Metastases (mets) Treated With Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Trials

ByDenise A. Yardley, MD,Yoon Sim Yap,Hamdy Abdel Azim,Richard De Boer,Mario Campone,Alistair Ring,Michelino De Laurentiis,Joyce A. O’Shaughnessy,Javier Cortes,Yogesh Chattar,Astrid Thuerigen,Juan Pablo Zarate,Liz Santarsiero

April 27th 2023

53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH,Frederik Marmé,Javier Cortes,Peter Schmid, MD,Delphine Loirat,Olivier Trédan,Eva Ciruelos,Florence Dalenc,Patricia Gómez Pardo,Komal L. Jhaveri,Rosemary Delaney,Theresa Valdez,Hao Wang,Wendy Verret,Sara M. Tolaney, MD, MPH

April 27th 2023

55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH,Javier Cortes,Giuseppe Curigliano,Erika P. Hamilton, MD,Sara A. Hurvitz, MD,Sibylle Loibl,Simona Scartoni,Tarek Sahmoud, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Joyce A. O’Shaughnessy

40th Annual Miami Breast Cancer Conference® - Abstracts

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data

3 Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience

4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study

5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above

12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)

13 Improved Sensitivity in Identification of ER- and HER2- Expressing Metastatic Breast Cancers With a Combination of Cell & Cell-Free Liquid Biopsy Analysis

15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib

16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy

17 A Clinical Systematic Literature Review of Treatments Among Patients With Advanced/ Metastatic HER2+ Breast Cancer

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

21 TIP ELECTRA: An Open- Label, Multicenter, Phase 1b/2 Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2– Negative (HER2–) Breast Cancer

24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study

25 Real-world BRCA1/2 Testing Patterns in HER2–Negative Early- Stage Breast Cancer (eBC) Patients

26 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), Vs Investigator’s Choice of Endocrine Monotherapy for ER+/HER2– Advanced/ Metastatic Breast Cancer (mBC)

27 TIP XMT-1660: A Phase 1b Trial of a B7-H4 Targeted Antibody- Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers

28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

33 Real-world Patient Characteristics, Treatment Patterns, and Outcomes Among Patients With Metastatic Breast Cancer and BRCA Mutations Treated Off-label With Talazoparib

35 TIP A Pragmatic Clinical Trial to Determine the Best Treatment Decision in Relapsed Metastatic Breast Cancer With Discordant Tumor Receptors

37 Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined With Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies

44 Results From the Phase 1/2 Study of Patritumab Deruxtecan (HER3-DXd), a HER3-Directed Antibody-Drug Conjugate (ADC), in Patients (pts) With HER3- Expressing Metastatic Breast Cancer (MBC)

48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study

50 Pooled Exploratory Analysis of Survival in Patients (pts) With HR+/ HER2− Advanced Breast Cancer (ABC) and Visceral Metastases (mets) Treated With Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Trials

53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)

55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

Trending on CancerNetwork

KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma

KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma

Creating a “Watershed Moment” for Novel Therapeutic Access in Lymphoma

FDA Grants FTD to WTX-124 in Advanced Pretreated Cutaneous Melanoma

How Does One Manage Talquetamab’s Unique AE Profile in Multiple Myeloma?